SCHEMBL470269

SCHEMBL470269

Cc1nc2c(-c3cccc(Cl)c3)cnn2c(-c2ccc3c(c2)CCCO3)c1C(OC(C)(C)C)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 0.46
CYP3A4 P08684 2/20 0.42
PSIP1 O75475 1/20 0.40
FABP4 P15090 4/20 0.37
GPR119 Q8TDV5 1/20 0.36
NPC1 O15118 1/20 0.35
HCRTR1 O43613 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
MAPK1 P28482 1/20 0.35
RAB9A P51151 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
DPP4 P27487 1/20 0.34
FABP3 P05413 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL461603 0.93 NR1I2 (0.39) NR1I2CYP3A4PSIP1FABP4GPR119
SCHEMBL462755 0.93 NR1I2 (0.51) NR1I2CYP3A4PSIP1NPC1ALDH1A1
SCHEMBL462760 0.86 NR1I2 (0.44) NR1I2CYP3A4PSIP1NPC1ALDH1A1
SCHEMBL470266 0.83 NR1I2 (0.68) NR1I2CYP3A4GPR119NPC1HCRTR1
SCHEMBL462405 0.83 NR1I2 (0.47) NR1I2CYP3A4PSIP1
SCHEMBL461169 0.80 DPP4 (0.46) NR1I2CYP3A4PSIP1GPR119NPC1
SCHEMBL12091046 0.79 NR1I2 (0.68) NR1I2CYP3A4PSIP1ALDH1A1
SCHEMBL461512 0.78 NR1I2 (0.60) NR1I2CYP3A4GPR119NPC1HCRTR1
SCHEMBL461802 0.77 NR1I2 (0.61) NR1I2CYP3A4PSIP1NPC1ALDH1A1
SCHEMBL470438 0.77 NR1I2 (0.63) NR1I2CYP3A4PSIP1NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633200-B2 Inhibitors of human immunodeficiency virus replication BRISTOL-MYERS SQUIBB COMPANY (US) 2014-01-21 US disclosed
US-8633200-B2 Inhibitors of human immunodeficiency virus replication BRISTOL-MYERS SQUIBB COMPANY (US) 2014-01-21 US disclosed
US-8633200-B2 Inhibitors of human immunodeficiency virus replication BRISTOL-MYERS SQUIBB COMPANY (US) 2014-01-21 US disclosed
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication BRISTOL-MYERS SQUIBB COMPANY 2012-09-06 US disclosed
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication BRISTOL-MYERS SQUIBB COMPANY 2012-09-06 US disclosed
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication BRISTOL-MYERS SQUIBB COMPANY 2012-09-06 US disclosed
WO-2012033735-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication EIF2AK2, RTF2, MAVS NR1I2 3085/4885CYP3A4 1719/4885PSIP1 1676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.